AIM: To assess feasibility, tolerability and efficacy of gemcitabine-based chemotherapy in patients ≥ 75 years old with advanced pancreatic cancer. METHODS: All consecutive patients ≥ 75 years old with advanced pancreatic adenocarcinoma were included in this retrospective study. Necessary criteria to receive chemotherapy were: performance status 0-2, adequate biological parameters and no serious comorbidities. Other patients received best supportive care (BSC). RESULTS: Thirty-eight patients (53% women, median age 78 years, range 75-84) with pancreatic cancer (metastatic: n = 20, locally advanced: n = 18) were studied. Among them, 30 (79%) were able to receive chemotherapy [median number: 9 infusions (1-45)]. Six patients (23%) had at least one episode of grade 3 neutropenia and one patient developed a grade 3 hemolytic-uremic syndrome. No toxic death occurred. Three patients (11%) had a partial tumor response, 13 (46%) had a stable disease and 12 (43%) had a tumor progression. Median survival was 9.1 mo (metastatic: 6.9 mo, locally advanced: 11.4 mo). CONCLUSION: Tolerance and efficacy of gemcitabine-based chemotherapy is acceptable in elderly patients in good condition, with similar results to younger patients.
AIM: To assess feasibility, tolerability and efficacy of gemcitabine-based chemotherapy in patients ≥ 75 years old with advanced pancreatic cancer. METHODS: All consecutive patients ≥ 75 years old with advanced pancreatic adenocarcinoma were included in this retrospective study. Necessary criteria to receive chemotherapy were: performance status 0-2, adequate biological parameters and no serious comorbidities. Other patients received best supportive care (BSC). RESULTS: Thirty-eight patients (53% women, median age 78 years, range 75-84) with pancreatic cancer (metastatic: n = 20, locally advanced: n = 18) were studied. Among them, 30 (79%) were able to receive chemotherapy [median number: 9 infusions (1-45)]. Six patients (23%) had at least one episode of grade 3 neutropenia and one patient developed a grade 3 hemolytic-uremic syndrome. No toxic death occurred. Three patients (11%) had a partial tumor response, 13 (46%) had a stable disease and 12 (43%) had a tumor progression. Median survival was 9.1 mo (metastatic: 6.9 mo, locally advanced: 11.4 mo). CONCLUSION: Tolerance and efficacy of gemcitabine-based chemotherapy is acceptable in elderly patients in good condition, with similar results to younger patients.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff Journal: J Clin Oncol Date: 1997-06 Impact factor: 44.544
Authors: C Louvet; R Labianca; P Hammel; G Lledo; M G Zampino; T André; A Zaniboni; M Ducreux; E Aitini; J Taïeb; R Faroux; C Lepere; A de Gramont Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544
Authors: Margaret Tempero; William Plunkett; Veronique Ruiz Van Haperen; John Hainsworth; Howard Hochster; Renato Lenzi; James Abbruzzese Journal: J Clin Oncol Date: 2003-07-28 Impact factor: 44.544
Authors: T Aparicio; J Desramé; T Lecomte; E Mitry; J Belloc; I Etienney; S Montembault; L Vayre; C Locher; J Ezenfis; P Artru; M Mabro; S Dominguez Journal: Br J Cancer Date: 2003-10-20 Impact factor: 7.640
Authors: Daneng Li; Marinela Capanu; Kenneth H Yu; Maeve A Lowery; David P Kelsen; Eileen M O'Reilly Journal: Clin Colorectal Cancer Date: 2015-05-22 Impact factor: 4.481
Authors: Jonathan J Hue; Katherine Bingmer; Kavin Sugumar; Lee M Ocuin; Luke D Rothermel; Jordan M Winter; John B Ammori; Jeffrey M Hardacre Journal: J Gastrointest Surg Date: 2021-02-25 Impact factor: 3.452
Authors: A R Lewis; C Cipriano; X Wang; R Ward; A Fitzpatrick; A R M Scott; A Rashed; H Raja; A Lamarca; R A Hubner; J W Valle; M G McNamara Journal: Med Oncol Date: 2019-09-06 Impact factor: 3.064
Authors: A M Nagrial; D K Chang; N Q Nguyen; A L Johns; L A Chantrill; J L Humphris; V T Chin; J S Samra; A J Gill; M Pajic; M Pinese; E K Colvin; C J Scarlett; A Chou; J G Kench; R L Sutherland; L G Horvath; A V Biankin Journal: Br J Cancer Date: 2013-11-21 Impact factor: 7.640
Authors: Carolyn H Kim; Diane C Ling; Rodney E Wegner; John C Flickinger; Dwight E Heron; Herbert Zeh; Arthur J Moser; Steven A Burton Journal: Radiat Oncol Date: 2013-10-16 Impact factor: 3.481